thirty-two of 36 patients ( 89 % ) had complete elimination of ventricular tachycardia from holter monitoring and only 2 patients had flecainide discontinued because of noncardiac side effects ( numbness , blurred vision and ataxia ) .
C0042514
ventricular tachycardia
C0016229
flecainide